1. MARKETS
  2. SECTOR : CHEMICALS & PETROCHEMICALS
  3. INDUSTRY : SPECIALTY CHEMICALS
  4. ROSSARI BIOTECH LTD.
Rossari Biotech Ltd.
NSE: ROSSARI | BSE: 543213

Rossari Biotech Live Share Price Today, Share Analysis and Chart

aboutRossari Biotech Ltd. is an Indian specialty chemical manufacturer providing sustainable chemical solutions across multiple industries. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC),... Read More
Export DemandEBITDA per Kg
Ask AI about Rossari Biotech
399.25-8.35(-2.05%)
52,882
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Slowing Down StockThese stocks have medium financials and valuations, but weak momentum indicating decreasing investor interestView SimilarEmbed DVM

Rossari Biotech Stock Price Analysis

Day Price Range

-2.0% 1 Day return
399.2 (LTP)
395412
LowHigh

Week Price Range

-3.7% 1 Week return
399.2 (LTP)
395417
LowHigh

Month Price Range

-4.5% 1 Month return
399.2 (LTP)
395459.8
LowHigh

52 Week Price Range

-37.7% 1 Year return
399.2 (LTP)
375654
LowHigh

Rossari Biotech Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

EPS forecast

CURRENT EPS
26.9
AVG. ESTIMATE
27
LOW ESTIMATE
25.6
HIGH ESTIMATE
27.8
CURRENT EPS
AVG. ESTIMATE

Consensus Recommendation

4 ANALYST Recommendations
BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Rossari Biotech Technical Analysis

Rossari Biotech EMA & SMA

Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
5 Day407.2
10 Day413.4
12 Day415.3
20 Day421.7
26 Day426.3
50 Day443.4
100 Day466.8
200 Day500.8

Rossari Biotech Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202657.8%
Week59.7%
Month54.5%

Rossari Biotech Active Candlesticks

Hikkake Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Rossari Biotech Resistance and Support

402.08
Pivot
First Resistance409.2
Second Resistance419.1
Third Resistance426.2
First Support392.2
Second Support385.1
Third Support375.2
Day RSI35.5
Day MACD-11
Day MFI44.8
Day MACD Signal Line-9.8

Rossari Biotech Beta

1 Month0.5
1 Year1.2
3 Month0.8
3 Year0.8

Rossari Biotech Price Change Analysis

↓-4.5%
Over 1 Month
LowHigh
395459.8
↓-20.8%
Over 3 Months
LowHigh
395540.0
↓-16.6%
Over 6 Months
LowHigh
395575
↓-37.7%
Over 1 Year
LowHigh
375654

Rossari Biotech Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Edward MenezesPromoter16,118,82029.1 %
Bhupesh Kumar LodhaPublic600,5001.1 %
Uti Aggressive Hybrid FundDii3,522,6456.4 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Rossari Biotech Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
BHUPESH KUMAR LODHABulkPurchase30 Apr 2026491.50298,000NSE
GOLDMAN SACHS INDIA FUND LIMITEDBlockSell20 Sep 20211478.65666,135BSE
GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIOBlockPurchase20 Sep 20211478.65666,135BSE
IIFL SPECIAL OPPORTUNITIES FUND SERIES 4BlockSell19 Jul 20211249.50166,875NSE
PUBLIC SECTOR PENSION INVESTMENT BOARDBlockPurchase19 Jul 20211249.50166,875NSE
PLUTUS WEALTH MANAGEMENT LLPBulkPurchase02 Sep 2020773.82300,000NSE
TWO ROADS TRADING PRIVATE LIMITEDBulkSell27 Jul 2020718.07280,400NSE
TWO ROADS TRADING PRIVATE LIMITEDBulkPurchase27 Jul 2020717.68280,400NSE
VAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITEDBulkSell24 Jul 2020758.44307,496NSE
VAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITEDBulkPurchase24 Jul 2020758.13307,496NSE

Rossari Biotech Corporate Actions

Rossari Biotech Dividend history and yield

Rossari Biotech dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Rossari Biotech dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
110 Jul 2026
0.5FINAL10 Jul 2026Equity Share
220 Jun 2025
0.5FINAL20 Jun 2025Equity Share
316 Aug 2024
0.5FINAL-Equity Share
424 May 2023
0.5FINAL-Equity Share
507 Jul 2022
0.5FINAL-Equity Share

Rossari Biotech Board Meetings

Rossari Biotech past and upcoming board meetings.

#Ex-Date
PurposeNotes
117 Oct 2026
Quarterly Results-
218 Jul 2026
Quarterly Results-
327 Apr 2026
Audited Results & Final Dividend-
417 Jan 2026
Quarterly Results-
515 Oct 2025
Quarterly Results-

Rossari Biotech Research Reports

Rossari Biotech research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
125 Oct 2026Deven Choksey472406.35Accumulate16.16%-1.75%pdf
219 Oct 2026ICICI Securities Limited520437.5Buy18.86%-8.74%pdf
320 Jul 2026ICICI Securities Limited
Target
605518.55Buy16.67%-23.01%pdf
420 Jul 2026Deven Choksey
Reco
Target
561518.55Accumulate8.19%-23.01%pdf
529 Apr 2026Deven Choksey604467Buy29.34%-14.51%pdf

Rossari Biotech Corporate Filings

Rossari Biotech BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
22 Oct 2026
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation of Transcript of Q2 & H1 FY27 for the Earnings Conference Call held on October 19, 2026
PDF
19 Oct 2026
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Conference Call for Q2 & H1 FY 27.
PDF
19 Oct 2026
Q2FY27 Quarterly Result Announced for Rossari Biotech Ltd.
Specialty Chemicals company Rossari Biotech announced Q2FY27 results Standalone Financial Highlights: Revenue from operations: Reached Rs 4,952.76 million in 'Q2FY27', representing an 18.06% YoY increase from Rs 4,195.12 million in 'Q2FY26', and a 2.70% QoQ growth from Rs 4,822.75 million in 'Q1FY27'. Total Income: Stood at Rs 4,969.62 million in 'Q2FY27', reflecting a YoY increase of 18.07% from Rs 4,209.09 million in 'Q2FY26', and a QoQ rise of 2.58% from Rs 4,844.63 million in 'Q1FY27'. Profit before Tax: Recorded at Rs 461.53 million in 'Q2FY27', indicating a 9.96% YoY growth from Rs 419.72 million in 'Q2FY26', but a marginal QoQ decline of 0.58% from Rs 464.21 million in 'Q1FY27'. Net Profit after Tax (PAT): Achieved Rs 342.31 million in 'Q2FY27', marking a 9.54% YoY increase from Rs 312.49 million in 'Q2FY26', and a slight QoQ decrease of 0.10% from Rs 342.66 million in 'Q1FY27'. For 'H1FY27', PAT stood at Rs 684.97 million. Consolidated Financial Highlights: Revenue from operations: Reached Rs 6,975.60 million in 'Q2FY27', demonstrating a YoY growth of 19.02% from Rs 5,861.07 million in 'Q2FY26', and remaining relatively flat QoQ with a 0.05% increase from Rs 6,972.00 million in 'Q1FY27'. Total Income: Stood at Rs 6,981.59 million in 'Q2FY27', showing an 18.79% YoY increase from Rs 5,877.11 million in 'Q2FY26', and a QoQ drop of 0.32% from Rs 7,003.87 million in 'Q1FY27'. Profit before Tax: Recorded at Rs 492.69 million in 'Q2FY27', representing a slight YoY decline of 0.81% from Rs 496.72 million in 'Q2FY26', but a 3.35% QoQ increase from Rs 476.72 million in 'Q1FY27'. Net Profit after Tax (PAT): Achieved Rs 389.07 million in 'Q2FY27', reflecting a 5.51% YoY growth from Rs 368.76 million in 'Q2FY26', and a QoQ increase of 10.86% from Rs 350.95 million in 'Q1FY27'. For 'H1FY27', consolidated PAT reached Rs 740.02 million. Business Highlights: Greenfield Expansion: The Board accorded its approval for the leasing of land by Rossari International Limited Company, a wholly-owned subsidiary, to set up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). Stock Options: During the quarter ended September 30, 2026, the Parent Company allotted 2,500 equity shares of Rs 2 each pursuant to the exercise of options under the approved Rossari Employee Stock Option Plan - 2019. Segment Reporting: The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered robust consolidated growth of 19% YoY in Q2FY27, achieving a record quarterly revenue of Rs 698 crore. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. We concluded the first half of FY27 on a strong note, with consolidated revenue of Rs 1,395 crore in H1FY27, a healthy growth of 23% YoY. The growth was broad-based, led by healthy volume, improved product mix and focused execution across our businesses. During Q2FY27, the HPPC, TSC and AHN businesses delivered YoY growth of 18%, 26% and 11%, respectively. Performance was supported by a higher contribution from value-added products and improved wallet share with customers across end-user industries. We continue to operate under dynamic business environment marked by raw material volatility, geopolitical uncertainty and cautious customer behaviour. Despite of these headwinds in Q2FY27 we maintained the gross margin at ~32% level and EBITDA margin at ~12.5% level. During H1FY27, we made progress in strengthening our balance sheet and improving cash flow generation. Our net working capital cycle improved to 86 days as of 30 September 2026, compared with 97 days as of 31 March 2026. Further, net debt declined to Rs 221 crore from Rs 281 crore over the same period. We are pleased to announce that the Board has approved the leasing of land to Rossari International Limited Company (RILC), our wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This builds on the in-principle approval granted by the Board earlier and marks a key milestone in Rossari’s international growth journey. Our strategic initiatives are progressing in the right direction. These include monetising non-core assets, rationalising lower-margin businesses and improving the product mix. We remain confident that operating leverage, scale benefits and these initiatives will support progressive improvement in profitability. With strong R&D; capabilities, expanding capacities, a healthy balance sheet and a growing global footprint, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained long-term growth.” Result PDF
PDF
18 Oct 2026
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for Q2 FY27 Results
PDF
18 Oct 2026
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
Intimation of Q2 & H1 FY27- Earnings Presentation
PDF

Rossari Biotech DocumentsAsk MarketMind AI

Rossari Biotech Earnings Call

Rossari Biotech earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
19 Oct 2026Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
04 May 2026Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
23 Jan 2026Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
27 Oct 2025Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
25 Jul 2025Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Rossari Biotech Annual Reports

Rossari Biotech financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026
2025Annual Report Mar-2025
2024Annual Report Mar-2024
2023Annual Report Mar-2023
2022Annual Report Mar-2022

Rossari Biotech Credit Ratings

Rossari Biotech credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
06 May 2026icra ratingsRossari Biotech LimitedUpdate on Material Event
03 Dec 2025icra ratingsRossari Biotech LimitedRatings reaffirmed and assigned for enhanced amount
23 Oct 2024icra ratingsRossari Biotech LimitedRatings reaffirmed; outlook revised to positive
08 Sep 2022icra ratingsRossari Biotech LimitedRossari Biotech Limited: Ratings reaffirmed
25 Jul 2021icra ratingsRossari Biotech LimitedRossari Biotech Limited- Update on Material Event

Rossari Biotech Investor Presentations

Rossari Biotech investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
19 Jul 2026Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
28 Apr 2026Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
18 Jan 2026Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
16 Oct 2025Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
20 Jul 2025Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation

Rossari Biotech - Company Profile

Rossari Biotech Management Structure

Rossari Biotech management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
PARUL GUPTACompany Secretary,Compliance Officer,Head(Legal.)-Mar 26
Mr. Ketan SablokGroup Chief Financial Officer-Mar 26
Mr. Mikhail MenezesDirector(Textile Business)-Mar 26
Mr. Yash ChariDirector(Business Division)-Mar 26
Mr. Puneet AroraBusiness Head(Textile,Strategies)-Mar 26
Mr. Prasad GadkariDirector(Manufacturing)-Mar 26

Rossari Biotech Board of Directors

Rossari Biotech Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Edward MenezesChairman/ED & CEO118.6Mar 26
Sunil ChariED / MD / Promoter57Mar 26
GURUDAS VISHWAS ARASIndependent Non Exe. Director45Mar 26
Esha AchanIndependent Non Exe. Director44Mar 26
Aseem DhruIndependent Non Exe. Director39Mar 26
Udey Paul Singh GillIndependent Director-Mar 26
PARUL GUPTACS / Compliance Officer / Legal Head-Mar 26

About the company - Business Profile

Rossari Biotech Ltd. is an Indian specialty chemical manufacturer providing sustainable chemical solutions across multiple industries. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). With over 25 years of experience, Rossari has established a strong market position as an agile and innovation-driven player in the specialty chemicals space.

Key Points

  • Key Facts:
    • Incorporated: March 2003 (converted into a joint stock company in 2009).
    • Headquarters: Mumbai, Maharashtra.
    • Stock Listing: Listed on BSE and NSE.
    • Global Presence: Exports to over 65 countries.
  • Operations and Resources:
    • Manufacturing Facilities: Operates 7 manufacturing facilities with a total installed capacity of 3,67,100 MTPA (including Unitop Chemicals and Tristar Intermediates).
    • R&D Capabilities: Maintains 4 R&D facilities. A new R&D facility was recently established at Koparkhairane, Navi Mumbai.
    • Product Portfolio: Over 4,300 products serving more than 3,010 customers.
  • Business Model and Strengths:
    • Rossari follows a B2B and B2B2C business model, focusing on customized specialty chemical solutions.
    • It excels in rapid product development and scaling, supported by an "asset-light" expansion strategy through acquisitions like Unitop Chemicals, Tristar Intermediates, and Romakk Chemicals.
  • Revenue Breakdown (FY 2024-25):
    • Total Consolidated Revenue: ₹2,080.3 crore.
    • By Segment:
      • HPPC: 76% (₹1,581 crore)
      • TSC: 18% (₹374.4 crore)
      • AHN & Others: 6% (₹124.8 crore)
  • Financial Highlights (FY 2025 vs FY 2026):
    • FY 2025 Revenue: ₹2,080.3 crore.
    • FY 2026 Revenue: ₹2,396.4 crore (15.2% Y-o-Y growth).
    • FY 2026 EBITDA: ₹286.0 crore (Margin: 11.9%).
    • FY 2026 PAT: ₹138.3 crore (Consolidated).
  • Innovation and Strategic Initiatives:
    • Sustainable Chemicals: Focus on eco-friendly products like silicones, enzymes, and bio-based surfactants.
    • Expansion: Establishing a new vitamin premix and minerals facility and expanding presence in Russia, Vietnam, and the Philippines.
    • Digitalization: Deployment of advanced ERP systems for supply chain optimization.
  • Workforce:
    • Total Workforce: 2,681 employees (as of March 2025).
    • Diversity: 202 women in the workforce; 50% women representation among Independent Directors.
  • Major Subsidiaries:
    • Unitop Chemicals Pvt. Ltd.
    • Tristar Intermediates Pvt. Ltd.
    • Buzil Rossari Pvt. Ltd. (BRPL).
    • Rossari Consumer Products Pvt. Ltd. (RCPPL).

References

  1. Annual Report Apr 2024
  2. Annual Report Apr 2025
  3. Investor Presentation Oct 2025
  4. Investor Presentation Jan 2026
  5. Result Jan 2026
  6. Investor Presentation Apr 2026

Rossari Biotech FAQ

Rossari Biotech today is trading in the red, down by 2.05% at ₹399.25.
Rossari Biotech is currently trading down 2.05% on an intraday basis. In the past week the stock fell 3.73%. Stock has been down 20.83% in the past quarter and fell 37.71% in the past year. You can view this in the share price history/seasonality section.
Rossari Biotech is listed on NSE with the ticker ROSSARI and on BSE as 543213. It's currently trading on NSE at a share price of ₹399.25 and on BSE with a share price of ₹398.
The market cap of Rossari Biotech is ₹2,211.61 Cr. as of Oct 30, 2026.
Rossari Biotech announced a FINAL dividend of 25% which equals ₹0.5 in Jul 10, 2026.The last three ex-dates for Rossari Biotech were Jun 20, 2025, Aug 16, 2024 and May 24, 2023. To view the full dividend history of Rossari Biotech click here.
Rossari Biotech has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Rossari Biotech reported ₹698.16 Cr. in revenue, ₹38.91 Cr. in net profit, and ₹87.57 Cr. in EBITD as of Oct 17, 2026 for Q2 FY26-27.
According to the predictions of 4 analysts, the share price prediction for Rossari Biotech is ₹575.5 with an upside of 44%.
The PE ratio of Rossari Biotech is 14.48 as of Oct 30, 2026.
The PB ratio of Rossari Biotech is 1.62 as of Oct 30, 2026.
You can view the latest analyst reports on the Rossari Biotech reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.